beta

ADAP

Adaptimmune Therapeutics Plc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Market Cap: 1.3 Billion

Primary Exchange: NASDAQ

Website: http://adaptimmune.com

Shares Outstanding: 130 Million

Float: 111 Million

Dividend: (%)

Beta: 1.35153067134933

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 1293 trading days

From: 2015-06-16 To: 2020-07-01

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud